MPM BioImpact

MPM BioImpact

Ansbert Gadicke established MPM Capital in 1992 after time at the Boston Consulting Group. He later added BioImpact Capital to handle private and public vehicles. The firm maintains its headquarters designation in Hong Kong while operating with a global team. MPM BioImpact deploys capital across venture funds, private-public impact funds, and a public equities strategy. It commits to early-stage, growth, late-stage, and public equities positions. Confirmed holdings include Orna Therapeutics, ElevateBio, Cullinan Therapeutics, and Werewolf Therapeutics. Co-investors on recent rounds include RA Capital Management, Redmile Group, and Novo Nordisk. The firm maintains activity in North America and Asia. The team exceeds twenty investment professionals plus Entrepreneur Partners. Additional offices support APAC coverage through Wu Jie. Kristen Laguerre oversees investment committees and portfolio construction. In 2019 Semma Therapeutics, a portfolio company, was acquired by Vertex for $950 million. MPM BioImpact maintains a hybrid structure that originates companies internally while also participating in external financings. Entrepreneur Partners hold operating roles at portfolio companies and serve on multiple boards simultaneously. This model creates direct governance links between capital allocation and company building.